A Phase 1 Study of ARQ 197 in Combination With Temsirolimus in Advanced Solid Tumors

Trial Profile

A Phase 1 Study of ARQ 197 in Combination With Temsirolimus in Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2016

At a glance

  • Drugs Tivantinib (Primary) ; Temsirolimus
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Dec 2016 Results published in the Investigational New Drugs
    • 19 Oct 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov
    • 15 Sep 2015 Planned End Date changed from 1 Jun 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top